In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus.
| INTRODUCTION
Type 2 diabetes mellitus (DM) is a highly prevalent risk factor for coronary artery disease, with an incidence that is increasing worldwide. In those who have established atherosclerosis, the presence of DM further increases future risk of ischemic events in a synergistic fashion. 1 DM multiplies cardiovascular (CV) risk not only in those with prior ischemic events, but also in those with stable coronary artery disease.
Heightened platelet activity appears to be present in atherothrombotic patients with DM. Long-term dual antiplatelet therapy (DAPT) reduces CV event rates in patients with acute coronary syndromes, both in the short-and long term. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Dual antiplatelet therapy appears to have a particular benefit in patients with prior myocardial infarction (MI) and diabetes. [12] [13] [14] [15] Whether that benefit extends to patients with diabetes and stable coronary artery disease without a history of prior MI remains a major unanswered question.
The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus
patients Intervention Study (THEMIS) trial was designed to evaluate the potential benefits and risks of dual antiplatelet therapy with ticagrelor plus low dose aspirin vs placebo plus aspirin in patients with established stable coronary artery disease and DM treated with medications.
twice daily. A protocol amendment enabling a dose reduction was finalized in May 2015, resulting in that approximately 25% of the randomized patients started on ticagrelor 60 mg twice daily or matching placebo. Because the lower dose was introduced rather early in the study, it is expected that at end of the study, at least 75% of the exposure time will be on 60 mg twice daily. The primary efficacy endpoint is a composite of CV death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. Table 2 provides further details about the pre-specified hierarchical testing of secondary endpoints. Appendix S1, Supporting Information provides the definitions.
All endpoints were adjudicated by a blinded academic clinical endpoint committee. Partway through the trial, given an increasing appreciation of the importance of peripheral artery ischemic endpoints, these were also adjudicated by a blinded academic clinical endpoint committee. [15] [16] [17] To ensure data integrity, there was a firewall maintained between the clinical endpoint committee (CEC) and the data monitoring committee (DMC). Specifically, the DMC statistical data analysis center (SDAC), handling all unblinded study data, was located at Duke Clinical Research Institute (DCRI).
The primary efficacy endpoint will be tested at a 4.96% significance level (two-sided), adjusted for 1 planned efficacy interim analysis with family-wise error controlled at 5%. The one planned efficacy interim analysis occurred on the 29th of March 2017. The recommendation from the DMC was to continue the study according to the protocol. The estimated annual event rate in the placebo arm was 2.5%.
An effect size of 16% relative risk reduction was hypothesized, with 1385 primary endpoint events needed to provide 90% power. This resulted in an estimated sample size of 19 000 patients, randomized in a 1:1 ratio, with an average follow-up time of 40 months (maximum 58 months). Even with the ticagrelor dosage switch, a power of 90% in the study is maintained, as the main analysis is based on randomization to ticagrelor irrespective of dose. • Provide informed consent prior to any study specific procedures
• Men or women ≥50 years of age
• Diagnosed with T2DM defined by ongoing glucose lowering drug treatment prescribed by a physician for treatment of T2DM since at least 6 months prior to 1st visit
• At high risk of CV events, defined as a history of percutaneous coronary intervention or coronary artery bypass graft or angiographic evidence of ≥50% stenosis of at least one coronary artery
Exclusion criteria
• Previous MI a except for definite secondary MI (eg, due to coronary revascularization procedure, profound hypotension, hypertensive emergency, tachycardia, or profound anemia)
• Previous stroke (TIA is not included in the stroke definition)
• Planned use of ADP receptor antagonists (eg, clopidogrel, ticlopidine, prasugrel), dipyridamole, or cilostazol. Planned use of aspirin >150 mg once a day
• Planned coronary, cerebrovascular, or peripheral artery revascularization
• Anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or CYP3A4 substrates with narrow therapeutic indices (quinidine, simvastatin >40 mg daily or lovastatin >40 mg daily) which cannot be stopped
• Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin (at venous thrombosis treatment not prophylaxis doses)
• Known bleeding diathesis or coagulation disorder, or uncontrolled hypertension (defined as a systolic BP ≥180 mm Hg and/or diastolic BP ≥100 mmHg)
• History of previous intracerebral bleed at any time, gastrointestinal bleed within 6 months prior to randomization, or major surgery within 30 days prior to randomization
• Increased risk of bradycardic events (eg, known sick sinus syndrome, second or third degree AV block, or previous documented syncope suspected to be due to bradycardia) unless treated with a pacemaker
• Known severe liver disease
• Renal failure requiring dialysis
• Pregnancy or lactation, and women of child-bearing potential not using reliable contraception
• Concern for inability to comply with study procedures and/or follow-up, or any conditions (judged by the investigator) that may render the patient unable to complete the study
• Any condition judged by the investigator that make participation unsafe or unsuitable, or any condition outside the atherothrombotic study area with a life expectancy <2 years
• Participation in another clinical study with an investigational product within 28 days prior to enrolment, or previous randomization to an investigational product in another ongoing clinical study. Participation in any previous study with ticagrelor. Previous randomization in the present study
• Involvement in the planning/conduct of the study There are no sub-studies planned, but predefined subgroup analyses will explore efficacy and safety according to baseline characteristics, such as revascularization history, single vs multivessel coronary artery disease, duration of diabetes, glycemic control, anti-diabetic medications, age groups, and renal function.
| RESULTS
A total of 20 108 patients were enrolled. Of these, 19 271 were randomized, and because of closure of a single site secondary for inadequate adherence to good clinical practice in a different trial, 19 220 patients are expected to be available for analysis (Figure 2 ).
The baseline characteristics and medications are described in Table 3 . The randomized population had a median age of 66 years and 31.4% were women. As expected in patients with DM, there was a high prevalence of concomitant hypertension and dyslipidemia. The prevalence of multivessel coronary artery disease was 62.1%, although 20.2% had no prior revascularization. The median duration of DM was 10.0 years, the hemoglobin A1c at baseline was 7.1%, and 28.7% of the patients were treated with insulin. At baseline, the population was very well-treated, with 89.8% on statins and 78.6% on an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
| DISCUSSION
The THEMIS trial was designed to address an important question in the management of patients with DM and stable coronary artery disease but no prior MI-does intensification of the antiplatelet regimen beyond aspirin reduce the risk of CV events? The trial is fully enrolled and well-powered to detect moderate relative risk reductions in the overall population studied. The sample size will hopefully allow examination of clinically logical and well-defined subgroups even if the overall trial does not meet its primary endpoint or shows marginal net clinical benefit. The evidence from THEMIS will complement that of several other trials which assessed the value of DAPT in patients with acute coronary syndromes or prior myocardial infarction. 2, 7, 11, 12, 15 When added to aspirin, ticagrelor specifically provides superior benefit compared with clopidogrel in patients with acute coronary syndromes 7 and compared with placebo in high-risk patients with prior myocardial infarction. 15 There is lack of clear benefit of ticagrelor monotherapy, compared with clopidogrel in peripheral artery disease 18 and compared with aspirin in ischemic stroke. 19 In the context of patients undergoing coronary stenting, there was no clear benefit to a strategy of DAPT for a month followed by ticagrelor monotherapy over a more conventional strategy of DAPT for a year followed by aspirin monotherapy, although additional study is ongoing in this regard. [20] [21] [22] There is evidence that platelet aggregation is enhanced in patients with DM compared with those without DM and that aspirin may have reduced efficacy in DM. 23 This appears to be because of several factors, including accelerated platelet turnover. Indeed, there is some evidence that twice daily administration of aspirin is more effective at inhibition of generation of thromboxane than once a day administration. 24, 25 In addition, enteric coated aspirin is widely used and appears to be somewhat less effective than non-enteric coated aspirin in pharmacodynamic and pharmacokinetic analyses. 26 Recent data suggest that aspirin has only a very modest effect for primary prevention CV events in patients with DM. [27] [28] [29] Similarly, there is also evidence of reduced pharmacodynamic and pharmacokinetic efficacy of clopidogrel among patients with DM, in part because of less efficient metabolism of clopidogrel as a prodrug. [30] [31] [32] [33] However, the clinical implications of these observations are not entirely clear since clopidogrel did not appear less effective in patients with DM in a large outcome trial of clopidogrel vs aspirin. 34 With more effective oral ADP receptor antagonists than clopidogrel, such as prasugrel or ticagrelor, there is no evidence of reduced efficacy in patients with DM who present with acute coronary syndromes or long-term post-MI. 14, 35, 36 In particular, some of the concerns regarding the efficacy of aspirin are related to short plasma residence time of the drug, while there is accelerated platelet generation during the 24-hour cycle. As ticagrelor is a reversible inhibitor of the P2Y 12 receptor, it is given twice daily. This results in persistent plasma levels that may be able to antagonize the P2Y 12 receptor in newly formed platelets around the entire circadian cycle. These observations led to the hypothesis of the THEMIS trial that DAPT with ticagrelor plus aspirin would be superior to aspirin alone even in DM patients with stable coronary artery disease. 14 The baseline characteristics of the THEMIS population suggest that it is very representative of daily practice in the care of DM patients. Thus, the results of THEMIS should be quite generalizable to the large number of patients with DM and stable coronary artery disease worldwide. Furthermore, the background medical therapy, such as statin use, is excellent, and therefore any observed benefits would truly be an incremental advance.
Furthermore, THEMIS is the largest randomized trial of patients with DM performed to date. Beyond the randomized question being addressed, the THEMIS database will allow several important hypotheses to be tested in observational analyses using a large, wellcharacterized population of patients with coronary artery disease and DM.
Limitations include the lowering of dose that occurred partway through the trial from ticagrelor 90 mg twice daily to ticagrelor 60 mg twice daily, which reduces the statistical power to examine either dose alone. Given the overall similar efficacy but trend towards more bleeding and less tolerability of ticagrelor 90 mg twice daily compared with ticagrelor 60 mg twice daily in PEGASUS, the lowering of the dose in THEMIS should impact efficacy less but could overestimate the overall bleeding risk, which is a conservative approach. [37] [38] [39] Multiple subgroup analyses have been prespecified, such as patients with multivessel coronary artery disease and prior percutaneous or surgical revascularization, but despite its size, the trial may not be well powered for subgroup analysis. Some peripheral ischemic events may not have been captured, as adjudication of these endpoints were added partway through the trial, though the trial was still blinded when this occurred, thus any assessment should be unbiased.
| CONCLUSION
Approaches to reduce CV morbidity further in patients with DM with stable atherosclerosis are urgently needed. More intense antiplatelet therapy is a promising approach. The THEMIS trial is assessing whether DAPT with ticagrelor and low-dose aspirin provides a significant reduction in ischemic events with an acceptable increase in bleeding. If the trial is positive overall, it will change the treatment paradigm for patients with diabetes. If the trial is clearly negative overall and in all major subgroups, it will provide a clear risk level below which more intense antiplatelet therapy is not indicated. Thus, irrespective of the exact results, THEMIS should greatly refine our understanding of the role of DAPT in patients across the atherothrombotic spectrum.
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